Abstract: The present invention relates to a long term storage stable multi-dose ready-to use or ready-to dilute pharmaceutical liquid formulation comprising pemetrexed or a pharmaceutically acceptable salt thereof, an antioxidant, a preservative, a buffering agent, and a pharmaceutically acceptable fluid. The invention also relates to a process of preparing the formulation, a kit and a method of treatment of patients having lung cancer by administering the pharmaceutical formulation to a subject in need thereof.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell-based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.

Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.

Abstract: Provided herein are methods treating follicular lymphoma (FL) in subjects having early disease progression after immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor. In certain embodiments, the methods comprise treating FL in subjects having disease progression within 24 months of initiating first-line or subsequent immunochemotherapy using a phosphoinositide-3-kinase (PI3K) inhibitor.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: A method for treating cancer. The method comprises treating a patient having a cancerous tumor with a gene inhibitor pre-operatively to inhibit upregulation of a particular gene, surgically removing the cancerous tumor, treating the patient with the gene inhibitor intra-operatively to inhibit upregulation of a particular gene, applying cold atmospheric plasma to surgical margins around the area in the patient from which the tumor was surgically removed, and treating the patient with the gene inhibitor post-operatively.

Abstract: Methods of treating cystic fibrosis transmembrane conductance regulator (CFTR)-mediated disease, such as cystic fibrosis, in patients with residual function mutations.

Abstract: Biocompatibie intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: A compound represented by formula (I), or an isomer, a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, pharmaceutically acceptable salts or a prodrug thereof.

Abstract: The present disclosure provides compositions and methods for treating ocular inflammation and ocular fibrosis and/or scarring using a cyclooxygenase 2 serine 516 acetylating agent alone or in combination with a cytosolic phospholipase A2 agonist.

Abstract: The present invention includes a molecule and method of identifying and a method of using the molecule to inhibit the interaction of A? and Drp1 proteins, including diethyl(3,4-dihydroxyphenethylamine)(quinolin-4-yl)methylphosphonate (DDQ); phosphonium,[10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate) (MitoQ); (3-Hydroxy-naphthalene-2-carboxylic acid (3,4-dihydroxy-benzylidene)-hydrazide (Dynasore); and/or (3-(2,4-Dichloro-5-methoxyphenyl)-2,3-dihydro-2-thioxo-4(1H)-quinazolinone, or derivatives thereof.

Abstract: Provided are methods of treating joint pain, comprising administering to a subject in need of joint pain treatment an effective amount of a pharmaceutical composition comprising a lipid mixture comprising one or more lipids; and an effective amount of an intra-articular steroid or a pharmaceutically acceptable salt thereof, wherein the therapeutic efficacy of the intra-articular steroid is sustained but the side effects associated with the intra-articular steroid are reduced.

Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Abstract: A method includes selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes. The method further includes selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from: fucosylated HMOs 2?-fucosyllactose (2?-FL), 3 -fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), and difucosyllactose (DFL); non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3?,6-di sialyllacto-N-tetraose (DSLNT), 6?-sialyllactose (6?-SL), and 3?-sialyllactose (3?-SL); and mixtures thereof.

Abstract: The present disclosure belongs to the biopharmaceutical field, and discloses uses of Trezastilbenoside in manufacture of a product for treating and/or preventing a disease of respiratory system, and particularly uses of Trezastilbenoside in manufacture of a product for treating and/or preventing a disease of respiratory system with symptoms of cough and/or expectoration and/or asthma. As indicated by the test results of the present disclosure, Trezastilbenoside has significant efficacy of relieving cough, eliminating phlegm, relieving asthma and anti-inflammation, and has a potential therapeutic effect on respiratory system diseases, thus possessing broad prospects in clinical application.

Abstract: The invention belongs to the technical field of biopharmaceuticals, and discloses the application of Trezastilbenoside in the manufacture of products for treating and/or preventing non-alcoholic fatty liver disease. The research of the present invention shows that after giving Trezastilbenoside to non-alcoholic fatty liver disease (NAFLD) model mice for 4 consecutive weeks, the serum TC, TG, and LDL content were all significantly reduced, and the HDL content was significantly increased, indicating that the drug has a lipid regulatory effect. The activities of AST and ALT in the serum were significantly weakened, and the infiltration of inflammatory factors in the liver tissue was reduced, indicating that the drug has a hepatoprotective effect. It can not only reduce the fat content of the liver, but also improve the pathological form of fatty liver, indicating an effect of against NASH.

Abstract: The present invention relates to pharmaceutical compositions comprising colloidal dispersions of silica particles to which silver ions have been adsorbed in combination with therapeutically active agents. It is also related to a kit of parts, uses and medical methods of treatment involving said pharmaceutical compositions or the components of said pharmaceutical composition. The invention provides means for alternative treatment strategies for bacterial infections to lessen the need for traditional antibiotics.

Abstract: Disclosed are the compositions comprising bioactive components Oroxylin A-7-glucuronide, Baicalein-7-glucuronide and Chrysin-7-glucuronide, isolated from the bark of Oroxylum indicum, and the process of isolating the said bioactive components.

Abstract: The present application relates to an orally administered pharmaceutical composition or kit for eradicating Helicobacter pylori, including a complex of a non-absorbable antibiotic and a clay mineral. The pharmaceutical composition and kit of the present invention may further include a ?-lactam antibiotic and/or a gastric acid inhibitor.

Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Abstract: The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein M1, R1, R2, and R3 are as described herein.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dentin-dental pulp disease or periodontal disease, a quasi-drug composition for preventing or improving dentin-dental pulp disease or periodontal disease or a health functional food composition for preventing or improving dentin-dental pulp disease or periodontal disease, all of which comprise a LPAR2 (lysophosphatidic acid receptor 2) inhibitor.

Abstract: One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Anti-Tumor Immune Enhancer (ATIE) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately.

Abstract: A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a ?-(1,3)-(1,4) glucan to the subject. Methods of immunostimulating in a subject by administering an effective amount of a ?-(1,3)-(1,4) glucan to the subject are also described.

Abstract: This disclosure relates to the use of an oxygen-containing liquid for treating a coronavirus infection, such as Covid-19.

Abstract: Provided is a metabolism improving agent that contains, for example, an alkalizing agent such as an acidosis improving agent or a urinary alkalizing agent as an active ingredient, and has actions such as improvement of insulin resistance, improvement of pituitary and adrenal functions, and reduction of visceral fat accumulation.

Abstract: The present invention relates to compositions and methods for controlling a gag reflex in a patient.

Abstract: Methods for the inactivation of highly resistant infectious agents, on inanimate or epithelial surfaces or in suspension, upon exposure to aqueous solutions or gels containing hypohalous acids, and the use of these preparations in the treatment, prevention, and interruption of transmission of contagious diseases, particularly infections of oral and genital mucosal and mucocutaneous epithelial surfaces.

Abstract: The present invention discloses targeting microRNAs as a potential therapeutic target for cancer, more particularly glioblastoma (GBM). It discloses targeting microRNAs with gold-nanoliposomes labeled with brain targeting-peptides inducing a significant cell growth arrest and inhibition of miRNA-92b, an aberrantly abundant miRNA found in GBM cells. Furthermore, it delivers gold-nanoliposomes to the brain by crossing the blood brain barrier (BBB) and reaching cancer tumors.

Abstract: The present disclosure relates to methods of identifying a cancer having sensitivity to an ATR inhibitor compound, and treating subjects with such identified cancers with the ATR inhibitor, particularly in combination with a DNA damaging agent.

Abstract: A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria.

Abstract: Provided herein are methods and compositions for the treatment of cancers with D-VC and arsenic trioxide. In some aspects, cancers for treatment according to the embodiments include cancers with increased GLUT1 expression and/or comprise KRAS mutation.

Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

Abstract: The invention provides compositions and methods for overcoming poor response to antibody therapy, for example, antibody resistance. The invention also relates to at least one immune receptor (IR) specific to the Fc receptor, vectors comprising the same, and recombinant T cells comprising the Fc immune receptor. The invention also includes methods of administering a modified T cell expressing an immune receptor that comprises a Fc binding domain.

Abstract: A chimeric antigen receptor is provided, including an extracellular segment, including a single-chain antibody region binding to an antigen human CD19 and a hinge region, a trans-membrane segment, including a trans-membrane domain of human CD8? linked to the hinge region of the extracellular segment and embedded in cell membrane of T lymphocyte, and an intracellular segment, including an intracellular domain of human CD8?, an intracellular domain of molecule 4-1BB and an intracellular domain of CD3 ? chain. The single-chain antibody region includes a heavy-chain variable region and a light-chain variable region of the single-chain antibody, the hinge region includes an extracellular domain of human CD8 alpha (CD8?) of 55 amino acid residues and three alanine residues (AAA) located at the N-terminal of the extracellular domain of human CD8?, and the intracellular domain of human CD8? includes seven amino acid residues and linked to the trans-membrane domain of human CD8?.

Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

Abstract: A method for sterilising a platelet lysate in the liquid state comprising at least the endogenous growth factors TGF-beta 1, EGF, PDGF-AB, IGF-1, VEGF and bFGF. The method comprising freezing the liquid platelet lysate in order to obtain a frozen platelet lysate, and irradiating the frozen platelet lysate with ionising radiation in order to obtain a sterilised platelet lysate, the irradiation being adapted so as to preserve at least 80% of the concentration of at least one of the endogenous growth factors chosen from the group consisting of TGF-beta 1, EGF, PDGF-AB, IGF-1 and VEGF.

Abstract: Disclosed are mesenchymal stem cell growth factor compositions and methods of their use to treat skin disorder, alleviate the effects of aging, treat wounds, orthopedic disorders, sexual dysfunction and/or reduce inflammation.

Abstract: The present invention relates to a pharmaceutical composition for treating cartilage damage, the composition comprising nasal septum chondrocytes (NSCs) as an active ingredient, and a method for producing the NSCs into a spheroidal shape. The NSCs enable the expression of type II collagen which is a constituent component of cartilage, and SOX9 which is involved in chondrogenic differentiation, and an excellent cartilage treatment effect was shown as a result of administrating spheroidal NSCs to an animal model of cartilage damage, and thus the pharmaceutical composition and the method for producing the NSCs, according to the present invention, may be useful employed in the field of autologous chondrocyte implantation.

Abstract: Disclosed are a multilayered cell sheet of cardiac stem cells (CSCs) and a method of manufacturing the same. In particular, the present disclosure provides a method of manufacturing a multilayered cell sheet according to a single step culture procedure by using, as a three-dimensional matrix, a biodegradable natural polymer hydrogel and embedding CSCs in the hydrogel. The multilayered cell sheet of the present disclosure does not require any special device for the manufacturing, is manageable with good physicomechanical property, increases a cell engraftment rate after transplantation based on sufficient accumulation of various growth and protective factors and extracellular matrix between cells, and is also self-assembled by the cell-mediated hydrogel compaction, making nutrients transfer easy. Therefore, the multilayered cell sheet of the CSCs is expected to be usefully applicable as a therapeutic agent for myocardium regeneration.

Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).

Abstract: Methods for accelerated cell lineage conversion and the treatment of patients with the lineage converted cells are provided. The methods include the steps of transfecting a cell with a composition that includes at least one synthetic mRNA encoding a chimeric protein that corresponds to an engineered fusion of a transcription factor and an heterologous peptide sequence derived from the C-terminal TAD of Gal4. The TAD domain enhances the epigenetic remodeling activity of the chimeric protein increasing the speed of lineage conversion. The converted cells may be used for research or administered to a human or animal patient as a therapy. In one preferred embodiment, the reprogramming of a somatic cell to pluripotency is accelerated by using a cocktail of mRNAs expressing a combination of wild-type or engineered reprogramming factors where Oct4 and/or Sox2 and/or Nanog are expressed as Gal4 TAD chimeras.

Abstract: The present invention provides a use of herb ferment for preparing a composition for preventing and/or treating obesity; wherein, the herb is Abelmoschus esculentus. The fermentation process of the present invention can enhance the content of total polysaccharide in the herb ferment, and effectively increase the amylase inhibition rate and the glucosidase inhibition rate of the herb ferment to effectively inhibit the decomposition and absorption of starch and glucoside. The herb ferment of the present invention can also effectively reduce the blood glucose of subjects after meals, and can effectively reduce the body weight, BMI value, waist circumference, visceral fat, average whole body fat percentage, and average body fat percentage, and can be effectively used to regulate blood glucose and blood lipids for weight loss. The herb ferment is prepared by fermenting the herb extract to yeast and lactic acid bacteria.

Abstract: Provided are compositions comprising a bacterial strain of the genus Blautia, for use in a method of increasing the microbiota diversity and/or stability of the microbiota of a subject.

Abstract: Our client, Seres Therapeutics, has asked us to file a new provisional application related to bacterial compositions and the use of such compositions for the treatment of inflammatory bowel disease.

Abstract: Provided are means, methods, and compositions effective for obesity treatment using probiotics such as bifidobacteria or lactobacilli. Also, a method of selecting probiotic bacteria having a body fat reducing effect, and a method of selecting responders to probiotic bacteria having an anti-obesity action are provided. Provided is a composition for reducing body fat, or the like, which contains Bifidobacterium and/or lactobacilli as an active ingredient, and is used for a pre-obesity group or an obesity disease including intestinal flora in which the ratio of the phylum Firmicutes to the phylum Bacteroidetes has a high value.

Abstract: A novel agent useful for improving brain function is provided. The active ingredient in this agent is a Bifidobacterium breve and/or a Bifidobacterium breve-containing cultured material is provided.

Abstract: Compositions for affecting the intestinal microbiome of a mammalian subject can include a pharmaceutically-acceptable carrier and greater than or equal to 1×104 PFU/mL or PFU/mg of bacteriophage having a tropism that includes an obesogenic and/or inflammatory bacterium associated with an intestinal microbiome of a mammal. Processes for preparing the disclosed compositions can include isolating the bacteriophage from an environmental source, characterizing the bacteriophage, and combining the bacteriophage with the pharmaceutically acceptable carrier at greater than or equal to 1×104 PFU/mL or PFU/mg. Methods can include administering the disclosed compositions to a mammalian subject with or without co-administration of the disclosed probiotics.

Abstract: This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.